Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ALDX
Stock Latest News
The Fly
Aldeyra receives orphan designation from EMA for ADX-2191
1M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
1M ago
8K
ALDX
Premium
The Fly
Aldeyra granted fast track designation for ADX-2191 by FDA
1M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
1M ago
ALDX
Premium
Ratings
Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
2M ago
ALDX
Premium
The Fly
Aldeyra receives orphan designation for ADX-2191 from EMA
2M ago
ALDX
Premium
Company Announcements
FDA Accepts Aldeyra’s Reproxalap Application for Review
2M ago
8K
ALDX
Premium
The Fly
Aldeyra announces FDA acceptance for review of reproxalap NDA
2M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
3M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
3M ago
8K
ALDX
Premium
The Fly
Aldeyra receives special protocol assessment agreement letter from FDA
3M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
3M ago
ALDX
Premium
Company Announcements
Aldeyra Resubmits Reproxalap NDA to FDA
3M ago
8K
ALDX
Premium
The Fly
Aldeyra resubmits topical ocular reproxalap NDA to FDA
3M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Holds Annual Meeting with Key Votes
4M ago
8K
ALDX
Premium
Ratings
Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating
4M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships
4M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
5M ago
ALDX
Premium
Ratings
Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
5M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
5M ago
8K
ALDX
Premium
The Fly
Aldeyra’s reproxalap achieves primary endpoint in Phase 3 dry eye disease trial
5M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Appoints Chip Clark to Board
5M ago
8K
ALDX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
